LOGIN
 
Share Page:
Back

Volume 17 , Issue 4
July/August 2002

Pages 557–566


The Endoscopically Controlled Osteotome Sinus Floor Elevation: A Preliminary Prospective Study

Emeka Nkenke, MD, DDS, Andreas Schlegel, MD, DDS, Stefan Schultze-Mosgau, MD, DDS, PhD, Friedrich W. Neukam, MD, DDS, PhD, Jörg Wiltfang, MD, DDS, PhD


PMID: 12182299

Purpose: It was the aim of the present prospective study to quantify the gain in height of implant sites by endoscopically controlled osteotome sinus floor elevations (ECOSFE) with simultaneous implant placement and to report the number of sinus membrane perforations. Materials and Methods: From October 1999 to December 2000, of 92 sinus floor elevations, 18 were carried out endoscopically controlled with an osteotome technique. As augmentation material, -tricalcium phosphate (-TCP) or autogenous bone was used; 22 implants were placed. Results: The residual height of the alveolar crest in the posterior maxilla was 6.8 ± 1.6 mm on average. The implant lengths ranged from 10 to 16 mm (mean implant length 12.2 ± 1.4 mm). They were significantly larger than the residual height of the alveolar crests (P < .0005). Elevation of the sinus floor with an osteotome had to be supported by conventional sinus floor elevation instruments after a mean elevation of 3.0 ± 0.8 mm to prevent perforation of the sinus membrane. However, 1 perforation occurred, which was repaired with a periosteal patch. At stage 2 surgery, 2 implants were removed because of mobility. Endoscopic control revealed one case in which -TCP could be found within the sinus; another case showed areas of polypoid mucosa on the sinus floor. Discussion: With the ECOSFE, perforations of the sinus membrane can be visualized; however, they cannot be avoided. Although this technique is less invasive than the lateral window technique, it cannot be recommended as a standard procedure in the posterior maxilla because of the large amount of additional equipment needed and the technically demanding procedure. Conclusion: The use of the ECOSFE should be confined to scientific trials. (INT J ORAL MAXILLOFAC IMPLANTS 2002;17:557–566)


Full Text PDF File | Order Article

 

 
Get Adobe Reader
Adobe Acrobat Reader is required to view PDF files. This is a free program available from the Adobe web site.
Follow the download directions on the Adobe web site to get your copy of Adobe Acrobat Reader.

 

© 2014 Quintessence Publishing Co, Inc JOMI Home
Current Issue
Ahead of Print
Archive
Author Guidelines
About
Accepted Manuscripts
Submission Form
Submit
Reprints
Permission
Advertising
Quintessence Home
Terms of Use
Privacy Policy
About Us
Contact Us
Help